Clinical trial · no report yet · Phase 2
EBIN
Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib
- NCT03235245 ↗
- Active not recruiting
- European Organisation for Research and Treatment of Cancer - EORTC
- 14 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 7 | |
| Podcasts | 4 | |
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Unresectable Stage III Melanoma; Stage IV Melanoma
- Interventions
- Nivolumab + Ipilimumab; Encorafenib + Binimetinib
- Arms
- ARM A: Nivolumab + Ipilimumab · Active comparator
- ARM B: Encorafenib + Binimetinib + Nivolumab + Ipilimumab · Experimental
- Enrollment
- 271
- Primary outcomes
- Progression Free Survival (PFS)
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Start
- Oct 30, 2018
- Primary completion
- Oct 24, 2023
- Results posted
- No
- Registry record
- NCT03235245 · updated Aug 1, 2025
Publications
linked from the registry- Robert C, Kicinski M, Dutriaux C, Routier E, Govaerts AS, Buhrer E, Neidhardt EM, Durando X, Baroudjian B, Saiag P, Gaudy-Marqueste C, Ascierto PA, Arance A, Russillo M, Perrot JL, Mortier L, Aubin F, Dalle S, Grange F, Munoz-Couselo E, Mary-Prey S, Amini-Adle M, Mansard S, Lebbe C, Funck-Brentano E, Monestier S, Eggermont AMM, Oppong F, Wijnen L, Schilling B, MandalA M, Lorigan P, van Akkooi ACJ. Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study. Lancet Oncol. 2025 Jun;26(6):781-794. doi: 10.1016/S1470-2045(25)00133-0. PubMed 40449497